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Abstract 
Short-lasting unilateral neuralgiform headache attacks with conjuntival injection and tearing (SUNCT) is considered 
a rare trigeminal autonomic cephalgias, a group of primary headache disorders characterized by brief episodes of se-
vere unilateral headache in the distribution territory of the trigeminal nerve, accompanied by prominent ipsilateral and 
cranial parasympathetic autonomic features. The present report describes a SUNCT syndrome in a 64-year-old male 
who had been diagnosed with trigeminal neuralgia several years ago. The patient reported stabbing pain in the orbital 
zone and in the left upper maxillary region, of great intensity, brief duration, and a frequency of 20-100 attacks a day. 
Pain episodes were accompanied by conjunctival injection and tearing. Based on the anamnesis, clinical examination 
and a magnetic resonance imaging scan, episodic SUNCT syndrome was diagnosed and pharmacological treatment 
with topiramate was started. This reduced the intensity and number of attacks to 3-6 a day.
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Introduction
The trigeminal autonomic cephalgias (TACs) are a 
group of primary headache disorders characterized by 
brief episodes of severe unilateral headache in the distri-
bution territory of the trigeminal nerve, accompanied by 
prominent ipsilateral and cranial parasympathetic auto-
nomic features (CPAFs) (1). TACs are comprised in sec-
tion 3 of the International Classification of Headaches 
Disorders (1), third edition-beta (ICHD-3ß) and include: 
cluster headache (CH), paroxysmal hemicrania (PH), 
short lasting neuralgiform headache attacks, hemicrania 
continua (HC) and probable TAC (1). These conditions 
are distinguished by their attack duration and frequency, 
as well as response to treatment (2). 
Short-lasting unilateral neuralgiform headache attacks 
with conjuntival injection and tearing (SUNCT) and 
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short-lasting unilateral neuralgiform headache attacks 
with cranial autonomic symptoms (SUNA) are the two 
subsets of the ICHD-designated short lasting neuralgi-
form headache attacks (1). Characteristically they are 
moderate to severe, short-lasting strictly lateralized hea-
daches, with prominent ipsilateral CPAFs. As for the 
other TACs, episodic and chronic forms of SUNCT and 
SUNA are reported (1). The term SUNCT is adopted 
when CPAFs consist exclusively of conjunctival injec-
tion and tearing (2). 
SUNCT syndrome is considered a rare condition cha-
racterized by moderate or severe neuralgiform pain ty-
pically located in the area of the first division of the tri-
geminal nerve –though can be felt anywhere in the head. 
Attack episodes are very short (5 to 240 seconds) and 
can be described as single stabs, series of stabs or in a 
sawtooth pattern. As previously mentioned, such symp-
toms are accompanied by the CPAFs manifestations of 
conjunctival injection and lacrimation of the ipsilateral 
eye. Although attacks occur up to 60 times a day (range 
3 to 200), at least 20 attacks a day with a frequency of at 
least one a day for more than half of the time when the 
disorder is active have to be reported to fulfil diagnosis 
criterion. Table 1 provides the most relevant characteris-
tics to be noted in order to establish a differential diag-
nosis (1-8).
The attacks may be spontaneous or can be triggered by 
mechanical stimuli in the territory innervated by the tri-
geminal nerve, without refractory periods subsequent to 
them in most of patients (7,8). In the course of a SUNCT 
attack, hyperventilation and cardiovascular changes oc-
cur before and during the attack. Additionally, increa-
sing intraocular pressure, as well as facial and periocular 
temperature has been also recorded (8).
Management of this disorder is complex since no 
treatment is effective at all. Although intravenous lido-
caine can be used as a transitional treatment until bene-
ficial effects of a preventive treatment becomes evident, 
Characteristics Cluster
headache
Paroxysmal 
hemicrania
SUNCT
headache
Hemicrania continua
EPIDEMIOLOGY
Gender •	 (♂:♀) 3:1 1:2 M=F 4:1 8:1 1:1.6
Prevalence•	 0.9% 0.02% Very rare Very rare
Age at onset•	 28-30 years 20-40 years 20-50 years 30 years
PAIN
Description•	 Lancing/pulsatile/
stabbing
Pulsatile Stabbing or 
pulsatile
Throbbing/sharp/
constant
Intensity•	 Very severe Very severe/severe Severe/moderate Moderate/Severe
Location•	 Periorbital Orbital/temporal Orbital/temporal Orbital/Temporal
Duration•	 15-180 min./attack 2-45 min./ attack 5-240 s./ attack -
Frequency•	 1-10 attacks/day 1-40 attacks/day 3-200 attacks/day Continuous with 
exacerbations
Cuttaneous trigger•	 Absent Absent Present Absent
Remission periods >1 month (episodic)
< 1 month (chronic)
1 month – some 
years
1 week – years Absent
Autonomic phenomena ++++ ++++ +++ +++
Circadian rhythm ++ + - -
Predisposing factor: alcohol ++++ ++ + +++
TREATMENT
Indomethacin•	 - ++++ - ++++
Oxygen•	 +++ - - -
Sumatriptan•	 ++++ ++ + -
Table 1. Diagnostic criteria of the trigeminal autonomic cephalgias. + rare, ++ infrequent, +++ frequent, ++++ very frequent.
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Fig. 1. Left eye of the patient during a SUNCT syndrome attack.
Fig. 2. Magnetic resonance imaging scan without apparent alterations.
lamotrigine and topiramate are considered the most 
effective drugs for the preventive treatment of SUNCT 
(6,9,10). Response to sodium valproate, duloxetine, ga-
bapentin, oxcarbazepine and carbamazepine has been 
shown less effective (6,9). In contrast to PH, indome-
thacin is typically ineffective, whereas oxygen and su-
matriptan are unhelpful in opposition to CH (6). If drug 
treatment fails, surgery procedures such as ablative pro-
cedures or deep brain stimulation of the posterior hypo-
thalamic region can be considered (9,11).
The aim of the present case report was to describe the 
main clinical features and treatment of a patient diagno-
sed with SUNCT. The study protocol was approved by 
the Ethical Committee for Clinical Research (CEIC) of 
the Dental Hospital of the University of Barcelona.
Case Report
A 64-year-old male came to the Temporomandibular Jo-
int and Orofacial Pain Unit of the School of Dentistry of 
the University of Barcelona with severe left facial pain. 
Patient’s pathological background comprised a stomach 
ulcer and arterial hypertension, controlled with omepra-
zole 20 mg orally (1 every 12 hours. (Omapren®, Lesvi, 
Sant Joan Despí, Spain)) and torasemide 10 mg orally (1 
every 24 hours. (Isodiur®, Italfarmaco, Milan, Italy)), 
respectively. The patient had been diagnosed with trige-
minal neuralgia (TN) three years ago, which was treated 
with carbamazepine 200 mg orally (1 ½ every 8 hours. 
(Tegretol®, Novartis, Barcelona, Spain)) and pregabalin 
75 mg orally (1 every 8 hours. (Lyrica®, Pfizer, New 
York, USA)). In the last four months he had noticed an 
increase in the intensity and frequency of the pain that 
prevented him from leading a normal life. The patient 
presented a worsened general appearance and was de-
pressed. Twenty days before, he had started treatment 
with indomethacin 25 mg orally (1 every 12 hours. (In-
acid®, Merck Sharp and Dohme, New Jersey, USA)), 
which he stopped taking on his own initiative due to a 
lack of symptoms improvement.
Based on an exhaustive anamnesis, the pain was identified 
as being of an electric stabbing nature, scored as 10/10 on 
the visual analog scale (VAS), and located in the orbital, 
periorbital, frontal and upper maxillary zone of the left 
side of the face. The pain proved spontaneous but was 
also triggered by speech, chewing, swallowing, sneezing, 
shaving, and even simple contact with the left side of the 
face. The frequency of attacks during the day was 20 to 
100 on average, though recently the number had increa-
sed considerably – affecting even sleep. Slight continuous 
discomfort was described between successive attacks. On 
the same visit we noted a pain attack with conjunctival 
injection and tearing of the left eye (Fig. 1).
Following the anamnesis, a general, regional and local 
exploration was performed. Several complementary tests 
were requested: a panoramic X-ray, magnetic resonance 
imaging and a neurological exploration. No disease of 
oral or dental origin was noted, and the neurological 
evaluation and magnetic resonance imaging scan eva-
luated by a neurologist showed no anomalies (Fig. 2).
Based on the data obtained, a tentative diagnosis of epi-
sodic SUNCT syndrome was established. Laboratory 
tests (complete blood count, renal and liver parameters 
and ions) requested revealed slightly elevated glutamyl-
transferase levels. After consultation with the personal 
physician of the patient, we started treatment with to-
piramate 25 mg orally (1 every 12 hours. (Topamax®, 
Janssen-Cilag, Madrid, Spain)) once informed consent 
was accepted. The carbamazepine dose was gradually 
reduced and finally suspended, while the topiramate 
dose was gradually increased to a dose of 200 mg a day, 
i.e., 4 every 12 hours. The patient was instructed to re-
gister the number of daily attacks in order to assess the 
effectiveness of treatment. In this way, a decrease was 
observed in the intensity and number of daily attacks (to 
3-6 per day) (Fig. 3).
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Fig. 3. Graphic representation of the number of daily attacks recorded by the patient in the first 
three months of treatment with topiramate. Treatment provided: (1) Tegretol® 200 mg (0,0,0), 
Topamax® 25 mg (1,0,1); (2) Topamax® 25 mg (2,0,1); (3) Topamax® 25 mg (2,0,2); (4) Topa-
max® 25 mg (2,0,3); (5) Topamax® 25 mg (3,0,3); (6) Topamax® 25 mg (3,0,4); (7) Topamax® 
25 mg (4,0,4).
Discussion
Since Sjaasted et al. (12) first described SUNCT in 1978, 
it has been considered a rare disorder, with an estimated 
prevalence of 6.6 per 100,000 and an annual incidence 
of 1.2 per 100,000 (10). According to the name of this 
syndrome (Short-lasting Unilateral Neuralgiform heada-
che with Conjunctival injection and Tearing), SUNCT 
is characterized by severe, short-lasting unilateral hea-
daches, with prominent ipsilateral conjunctival injection 
and tearing (1).
As in our case, SUNCT syndrome is often mistakenly 
diagnosed as trigeminal neuralgia (TN) because of the 
similarities between these entities (4,8). Both involve 
pain of short duration (5 to 240 seconds), in which trig-
gering factors can be observed, such as physical contact 
(touch), tooth brushing or chewing, among others (2,4). 
The differences are that SUNCT shows a predilection for 
males, with clear resistance to antineuralgic drug therapy, 
and presents autonomic manifestations. Thermography 
in turn yields different patterns for TN and SUNCT. Re-
fractory periods, which are typical of TN, have not been 
demonstrated in SUNCT. On the other hand, the location 
of SUNCT is typically periorbital – unlike TN, which in 
only very rare instances is confined to the territory of the 
first division of the trigeminal nerve. The presence or not 
of autonomic manifestations is of great help in establis-
hing a correct diagnosis of SUNCT syndrome (8).
In our case the patient avoided any contact with the left 
upper maxilla, whether palpation of the soft tissues or 
dental percussion, and the possibility of tooth pain had to 
be ruled out initially. There have been reports of SUNCT 
syndrome triggered by oral stimuli such as chewing, the 
consumption of hot or cold beverages, and tooth brus-
hing (5,8). A careful intraoral examination is required in 
order to rule out the possibility that the pain may be of 
dental origin –thereby avoiding unnecessary extractions 
or dental treatment resulting from a wrong diagnosis 
(13). Other potential triggering factors are facial skin 
stimulation (shaving, contact with cold air) and facial 
muscle or tongue movements. In this context, Cohen (6) 
reported that 79% of patients diagnosed with SUNCT 
presented skin stimuli as triggering factors.
Although SUNCT constitutes a primary headache, their 
manifestations should be in relation to another disorder 
such as intracranial tumours, cerebrovascular accidents 
injuries, arteriovenous malformations, hormonal altera-
tions, antineoplastic therapy, human immunodeficiency 
virus infection or chronic active hepatitis (5,14). As in 
our case, detailed clinical exploration and examination 
of the complementary tests seems to be essential in order 
to rule out such eventualities.
SUNCT syndrome treatment could be challenging since 
no treatment is effective at all and treatment recommen-
dations are difficult to establish since controlled studies 
are sparse, and the disease is moreover uncommon (4). 
Although multiple treatment options such as gabapentin, 
topiramate, intravenous lidocaine and intravenous phen-
ytoin have been proposed, lamotrigine has been conside-
red as the drug of choice for the preventive management 
of SUNCT (4). 
Intravenous lidocaine has been advocated for short-term 
prevention. This treatment offers long-lasting analge-
sia (up to 6 months after injection), and is of great help 
in acute presentations where the patient is extremely 
stressed and unable to lead a normal life. Intravenous 
lidocaine offers the advantage of obviating the need for 
any other medication for a certain period of time. The 
disadvantage is that it involves continuous intravenous 
infusion and thus requires cardiovascular monitorization 
– a situation that is scantly practical in the routine cli-
nical setting (3,5). As regards long-term prevention of 
the attacks, Cohen (6) reported a 68% success rate in 
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patients with SUNCT headache treated with lamotrigi-
ne (up to 300-400 mg/day), versus 42% with topiramate 
(up to 300-400 mg/day), and 45% with gabapentin (up 
to 3600 mg/day). Thus, the recommended first choice 
treatment consists of lamotrigine followed by topira-
mate. Other drugs such as sodium valproate and carba-
mazepine appear to be less effective. Carbamazepine at 
doses of up to 900 mg/day can offer good results when 
combined with prednisolone or topiramate (5).
After consultation with the personal physician of the 
patient, a gradually increasing administration of topira-
mate was performed. Although topiramate is not consi-
dered a first line treatment drug, a significantly reduc-
tion in severity and frequency of attacks was reported 
(Fig. 3). Topiramate is an anticonvulsant drug which 
exerts its action through blockade of the voltage-gated 
sodium channels, enhancing GABA-mediated chloride 
influx involving GABA-A receptor and antagonism of 
the glutamate kainate/AMPA receptor (15). Current do-
sing protocol recommends to start treatment with a low 
dose, followed by gradual increments until an effective 
dose level of 300 mg/day is reached. It is advisable to 
inform the patient of the need to maintain good hydra-
tion during the treatment, in order to reduce the risk of 
renal lithiasis and other adverse reactions related to fluid 
loss. During treatment with topiramate there have been 
reports of increased incidences of mood alterations and 
depression, and of a syndrome comprising acute myo-
pia associated with secondary narrow-angle glaucoma. 
During treatment with this drug, patients may develop 
metabolic acidosis secondary to a mild to moderate re-
duction of serum bicarbonate concentration. This gene-
rally occurs at the start of treatment, though it also may 
manifest at any time in the course of therapy. For these 
reasons adequate patient evaluation is recommended, 
including the determination of serum bicarbonate (15). 
Our patient underwent periodic controls both by our 
own Service and by his personal physician, with labora-
tory tests every 4-6 months in order to evaluate possible 
side effects of the drug. Nevertheless, further research is 
needed to clarify the therapeutic efficacy of topiramate 
in SUNCT syndrome.
In cases of medically intractable primary headaches, 
surgical management options such as neuromodulation, 
involving the injection of the combination of a steroid 
and a local anesthetic (e.g., depomedrone 80 mg and li-
docaine 2%) in the ipsilateral region of the greater occi-
pital nerve; electrical stimulation of the occipital nerve; 
and deep brain stimulation in the posterior region of the 
hypothalamus should be considered (5,6). 
Cohen (6), on the basis of functional imaging studies, 
recorded changes in blood oxygen load in the hypotha-
lamus during the activation produced in the course of 
spontaneous SUNCT attacks. The level of activation 
was related to the intensity of pain. Of the 9 SUNCT 
patients studied, 5 presented bilateral activation while 
two showed activation on the side contralateral to the 
attacks. This resulted in the suggestion that the hypo-
thalamus is the central generator of TACs, though this is 
not the case in patients with secondary SUNCT. Based 
on these observations, deep brain stimulation has begun 
to be applied to the posterior zone of the hypothalamus 
as a treatment strategy in severe cases of the disease, re-
fractory to drug treatment (7,9). This technique has been 
applied more often in cases of cluster headache, though 
it is also beginning to find application in the more se-
rious presentations of SUNCT – affording a marked re-
duction in pain attacks in both cases (11).
The effectiveness of hypothalamic stimulation in TACs 
has a number of physiopathological implications. The 
posterior zone of the hypothalamus receives informa-
tion from the trigeminal territories through the direct 
trigeminal-hypothalamic pathway. Direct electrical and 
peptidic stimulation of the posterior area of the hypo-
thalamus modulates the activity of the caudad nucleus 
of the trigeminal nerve. This explains why hypothala-
mic stimulation can restore hypothalamic modulation 
of the trigeminal caudad nucleus, preventing activation 
of the trigeminal reflex that is believed to be responsi-
ble for the pain and autonomic symptoms. This in turn 
supports the hypothesis that hypothalamic stimulation 
modulates the activity of the caudad nucleus of the tri-
geminal nerve, which controls the above mentioned tri-
geminofacial reflex of SUNCT (6,7,10,11). This seems 
to open the way to future treatment options, though it 
must be accepted that hypothalamic activity may not be 
the only mechanism involved in SUNCT. In order to re-
duce risks, electrical stimulation of the occipital nerve 
has been proposed – with good results in patients with 
cluster headache and paroxysmal hemicrania (6). Thus, 
the future of the treatment of this type of headache is 
based upon the investigation of its underlying physiopa-
thological mechanisms.
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